Skip to content
Peptide research

Mazdutide

Also known as IBI362 · LY3305677 · OXM3
Category
Weight Management & Metabolic
Administration routes
Injectable
Regulatory status
Not FDA-approved

What it is

A dual GLP-1 and glucagon receptor agonist for weight loss and blood sugar control. Human evidence for weight loss and glucose control is strong, though long-term safety data are limited and liver benefit evidence is weak. Gastrointestinal side effects are common, heart rate can rise, and hypoglycemia is a risk at higher doses, while thyroid tumor risk remains theoretical. It is not an approved drug in the US; supply is unregulated research-grade product.

Read Full record

Studied uses & evidence

Studied uses(7)

  • Significant Weight Loss

    High

    Phase 3 trial showed up to 14% body weight loss at 48 weeks versus placebo.

  • Glycemic Control

    High

    Human RCTs show significant HbA1c reduction; approved in China for type 2 diabetes.

  • Dual Mechanism of Action

    Medium

    GLP-1 effects proven in humans; added energy-expenditure benefit is mechanism-based, not directly measured.

Evidence limits

Evidence Level
Strong

Supported by multiple Phase 1b, Phase 2, and Phase 3 randomized controlled trials, two systematic reviews/meta-analyses, and regulatory approval in China. The GLORY-1 Phase 3 trial (NEJM, 2025) provided pivotal evidence for weight management. A Phase 2 trial in type 2 diabetes (Diabetes Care, 2023) demonstrated glycemic and weight benefits. Meta-analyses (Frontiers in Endocrinology, 2024; Diabetes Obesity & Metabolism, 2026) confirm consistent efficacy across trials. US Phase 2 results were published in August 2026.

Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)

Cautions & risk summary

Do not use if

  • Personal/family history of MTC

    Absolute

    Dual GLP-1/glucagon agonist carries thyroid C-cell tumor risk from GLP-1 component.

  • History of pancreatitis

    High

    GLP-1 class effect. Monitor for pancreatitis signs and symptoms.

  • Severe gastroparesis

    High

    GLP-1 component slows gastric emptying significantly.

General cautions

  • Pregnancy

    Absolute

    Investigational compound. No reproductive safety data.

Risk summary(9)

Risks = level of concern: High · Moderate · Low · Theoretical

  • Gastrointestinal adverse events: diarrhea (28-41%), nausea (21-25%), vomiting (12-16%), decreased appetite (27-31%), abdominal distension (4-12%)

    High
  • Heart rate increase: 5-17 bpm elevation above baseline observed across doses

    Moderate
  • Hypoglycemia risk: up to 16% at higher doses, especially when used with other antidiabetic agents; severe hypoglycemia rare

    Moderate
  • Injection site reactions: 4-6% incidence

    Low
  • Immunogenicity: treatment-induced anti-mazdutide antibodies detected in 10-20% of participants, though no impact on efficacy or safety observed

    Low
  • Potential thyroid C-cell effects: class concern for GLP-1 receptor agonists; no C-cell hyperplasia or thyroid tumors observed in trials but long-term surveillance needed

    Theoretical
  • Cardiovascular effects: supraventricular extrasystoles and sinus tachycardia observed in small percentages; all asymptomatic and transient

    Low
  • Limited long-term safety data: most evidence from trials of 20-48 weeks duration; post-marketing surveillance ongoing in China

    Moderate
  • Weight regain upon discontinuation: as with other GLP-1 agonists, weight regain expected after stopping treatment

    Moderate
Safety & interactions in Full record

Further reading

Read Full record

This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer

Compiled from published research indexed through March 2026.